UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study

Haematologica (Roma), 2024-03, Vol.109 (3), p.857-866

2024

Volltextzugriff (PDF)

Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer

Health and quality of life outcomes, 2024-09, Vol.22 (1), p.81-10, Article 81

2024

Volltextzugriff (PDF)

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

Orphanet journal of rare diseases, 2024-06, Vol.19 (1), p.241-10, Article 241

2024

Volltextzugriff (PDF)

Testimonials Versus Informational Persuasive Messages: The Moderating Effect of Delivery Mode and Personal Involvement

Communication research, 2008-10, Vol.35 (5), p.666-694

Braverman, Julia

2008

Volltextzugriff (PDF)

Discrete Emotions and Persuasion: The Role of Emotion-Induced Expectancies

Journal of personality and social psychology, 2004-01, Vol.86 (1), p.43-56

2004

Volltextzugriff (PDF)

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

Haematologica (Roma), 2021-12, Vol.106 (12), p.3240-3244

2021

Volltextzugriff (PDF)

Autism Treatment Evaluation Checklist (ATEC) Norms: A "Growth Chart" for ATEC Score Changes as a Function of Age

Children (Basel), 2018-02, Vol.5 (2), p.25

2018

Volltextzugriff (PDF)

Impact of acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy on health-related quality of life (HRQOL) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.294-294

2022

Volltextzugriff (PDF)

How do gamblers start gambling: identifying behavioural markers for high-risk internet gambling

European journal of public health, 2012-04, Vol.22 (2), p.273-278

2012

Volltextzugriff (PDF)

Accuracy of Self-Reported Versus Actual Online Gambling Wins and Losses

Psychological assessment, 2014-09, Vol.26 (3), p.865-877

2014

Volltextzugriff (PDF)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Journal of clinical oncology, 2023-01, Vol.41 (3), p.517-527

2023

Volltextzugriff (PDF)

Predictors of Medication Adherence for African American Patients Diagnosed with Hypertension

Ethnicity & disease, 2009-09, Vol.19 (4), p.396-400

2009

Volltextzugriff (PDF)

P-310 Treatment preferences among triple-class exposed patients with relapsed/refractory multiple myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a discrete choice experiment

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S209-S209

2023

Volltextzugriff (PDF)

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Blood, 2022-11, Vol.140 (Supplement 1), p.10930-10931

2022

Volltextzugriff (PDF)

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Blood, 2022-11, Vol.140 (Supplement 1), p.13259-13261

2022

Volltextzugriff (PDF)

A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology

Value in health, 2024-04, Vol.27 (4), p.458-468

2024

Volltextzugriff (PDF)

Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6567-6567

2022

Volltextzugriff (PDF)

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy: Qualitative analyses of pretreatment patient interviews in the KarMMa trial

Journal of clinical oncology, 2020-10, Vol.38 (29_suppl), p.155-155

2020

Volltextzugriff (PDF)

Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.454-454

2022

Volltextzugriff (PDF)

Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach

Quality of life research, 2024-04, Vol.33 (4), p.1075-1084

2024

Volltextzugriff (PDF)

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.3041-3041

2021

Volltextzugriff (PDF)

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Blood, 2021-11, Vol.138 (Supplement 1), p.2835-2835

2021

Volltextzugriff (PDF)

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Blood, 2021-11, Vol.138 (Supplement 1), p.4098-4098

2021

Volltextzugriff (PDF)

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

Leukemia research, 2023-06, Vol.129, p.107074-107074, Article 107074

2023

Volltextzugriff (PDF)

Development of the Mental Synthesis Evaluation Checklist (MSEC): A Parent-Report Tool for Mental Synthesis Ability Assessment in Children with Language Delay

Children (Basel), 2018-05, Vol.5 (5), p.62

2018

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Humans
(41)
Female
(27)
Male
(27)
Adult
(15)
Middle Aged
(15)
Aged
(14)
Biological And Medical Sciences
(14)
Social Sciences
(13)
Psychology
(12)
Oncology
(11)
Quality Of Life
(11)
Medical Sciences
(10)
Aged, 80 And Over
(9)
Dermatology
(9)
Skin Neoplasms - Prevention & Control
(8)
Carcinoma, Basal Cell - Prevention & Control
(7)
Carcinoma, Squamous Cell - Prevention & Control
(7)
Internet
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study

Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

Testimonials Versus Informational Persuasive Messages: The Moderating Effect of Delivery Mode and Personal Involvement

Discrete Emotions and Persuasion: The Role of Emotion-Induced Expectancies

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

Autism Treatment Evaluation Checklist (ATEC) Norms: A "Growth Chart" for ATEC Score Changes as a Function of Age

Impact of acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy on health-related quality of life (HRQOL) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

How do gamblers start gambling: identifying behavioural markers for high-risk internet gambling

Accuracy of Self-Reported Versus Actual Online Gambling Wins and Losses

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Predictors of Medication Adherence for African American Patients Diagnosed with Hypertension

P-310 Treatment preferences among triple-class exposed patients with relapsed/refractory multiple myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a discrete choice experiment

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology

Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy: Qualitative analyses of pretreatment patient interviews in the KarMMa trial

Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE)

Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

Development of the Mental Synthesis Evaluation Checklist (MSEC): A Parent-Report Tool for Mental Synthesis Ability Assessment in Children with Language Delay

Suchergebnisse filtern